These results highlight the TIM-3/Gal-9 axis as a potential biomarker of immune escape and proliferative activity in CRC, warranting further investigation as a therapeutic target in immunomodulatory strategies. The gene discussed is HAVCR2; the disease is colorectal carcinoma.